The fixed combination of brimonidine/timolol is more cost effective than dorzolamide/timolol, according to a study published in the September/October issue of the European Journal of Ophthalmology.
The fixed combination of brimonidine/timolol (Combigan;Allergan) is more cost effective than dorzolamide/timolol (Cosopt; Merck), according to a study published in the September/October issue of the European Journal of Ophthalmology.
A. Hommer, of the Krankenanstalt Sanatorium, Vienna, Austria, and colleagues conducted a review of the literature concerning the efficacy, tolerability and cost implications (across several European countries) of various IOP-lowering therapies administered for a three-month period.
The researchers determined equal efficacy of brimonidine 0.2% and dorzolamide 2% as either fixed combinations with or as adjunctives to timolol 0.5% therapy. At three and 12 months, however, the brominidine/timolol fixed combination proved to be the least costly option. Brimonidine as an adjunct to timolol was a more expensive alternative than the fixed combination, and dorzolamide as an adjunct to timolol represented a still more expensive option.
The team concluded that, as the efficacy was equal but the cost was lower, the brominidine/timolol fixed combination offered the greatest cost effectiveness in all countries studied of the IOP-lowering therapies reviewed.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.